🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

GMMG-HD6: Elotuzumab-RVD vs. RVD in newly diagnosed MM #mmsm The Lancet Haematology Elias K. Mai MD Elotuzumab resulted in no benefit👇 ➡️ thelancet.com/journals/lanha… IMO, Elotuzumab has no role in myeloma, even in relapsed refractory disease. Congrats for authors publishing -ve study

Did a deep dive today into LGL Nice algorithm on differentiating the 3 types! T-LGL = CD3+ TCR rearranged NK-LGL = CD3-, CD56+, KIR restricted Aggressive NK leukemia = EBV+ ncbi.nlm.nih.gov/pmc/articles/P…

ashpublications.org/hematology/art… Cool visual of all the rare syndromes associated with paraproteins Aaron Goodman - “Papa Heme” Manni Mohyuddin Rahul Banerjee, MD, FACP 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM

Are you a young European #oncologytrainee interested in developing your knowledge in #oncology? Discover more with the Basic Principles in Oncology Course! Apply by 18 Feb, you may be among the selected candidates to receive FREE REGISTRATION 👉 bit.ly/3RME0tt

What a view #Norway #Lofoten

The ESCO Mentorship programme for 2024 has begun with a series of preparatory online workshops for the mentees and the mentors run by Talent for Growth. It was also a great opportunity to exchange ideas and approaches...Good luck everyone! #ESOncology #ESOcollege #ESOexperience

Happy to announce the publication of my book # Povești medicale. The English version comes soon. Stay tuned.

Just out Timothée Olivier, MD and I review the Natalie study youtu.be/2FuTv-_TX7w?si…

Thanks Vinay for this interactive appraisal of the NATALEE trial ! - Adjuvant trial in breast - 3 years ribociclib (toxic + financial) - large inclusion criteria... ➡️worth having a look at the data very closely !👇

#ESHMDS2024 Conclusion of the day1: when no new drugs improving OS are approved in years, hematologist talk Prognostic Scores and WHO/ICC classification differences 🤦‍♂️

My comments at the FDA ODAC on MRD as an accelerated approval endpoint in Myeloma Safety is the big reason this is a bad decision

#ESHMDS2024 Conclusion of day2: MDS people want to learn from myeloma field and introduce surogate endpoints for their trials. A huge step backwards. Disappointed to see this reversal.

#ESHMDS2024->using surrogate endpoints (like CR) in MDS is a bad idea: 1) lack of validation 2) effect of CR on OS unclear-> not every CR translates into better OR 3) potential harm not to be excluded 4) CR will introduce incertainty in the field-> lower evidence quality

How applying FDA censoring rules can double the PFS benefit❓ Nice coverage by Vinay Prasad MD MPH in the Drug Development Letter of our paper recently published in EJC !👇 drugdevletter.com/p/fda-censorin…

Spin alert with TROPION-Lung01 ! A press release reporting a "clinically meaningful OS improvement" when it "did not reach statistical significance" ⁉️ What is "high level OS" exactly? @IsabelleBoutron et al. ➡️"spin" = "specific reporting strategies, whatever their motive, to

LAURA trial #ASCO2024 #ASCO24 main potential limitation is understaging of a significant proportion of patients who were actually metastatic, but did not have PET-CT at enrolment? Here is a visual superimposing curves with PACIFIC-EGFR subgroup👇

Another spin on a negative trial! What‘s next ? A censoring on AEs grade 5 ?

#ASCO24 #ASCO2024 postASCO! Vinay Prasad MD MPH and I discussed top abstracts Here is a 2:41 excerpt from the full video. TRANSMET: liver transplant in patients with liver colorectal metastases... with special insights! Full discussion here: drugdevletter.com/p/special-post…

Just out. Before and after studies in oncology. Do they even have a place in modern oncology? Check our new paper: karger.com/ort/article/do… Regression to the mean bias in before and after studies:

Calling all #patientadvocates and all #nurses! Join the ESO Improving Cancer Outcomes and Leadership course to gain essential skills in strategic planning and leadership. Apply by 7 Feb: bit.ly/3yl4POy #OncologyLeadership #CancerCare